Format

Send to

Choose Destination
Med Clin North Am. 2013 May;97(3):363-8. doi: 10.1016/j.mcna.2013.01.001. Epub 2013 Feb 16.

International Work Group criteria for the diagnosis of Alzheimer disease.

Author information

1
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. cumminj@ccf.org

Abstract

Alzheimer-type biomarker changes are identifiable in asymptomatic and mildly symptomatic predementia phases of Alzheimer disease (AD) and AD dementia. The International Work Group (IWG) guidelines for diagnosis identify a unified spectrum of 3 phases. The classic clinical feature that indicates AD is an episodic memory defect of the amnestic type. IWG criteria require biomarker support for the diagnoses of AD at any clinical stage. Pathophysiologic and topographic biomarkers are recognized. These criteria are proposed to allow highly specific diagnosis of AD and assist in identifying patients for clinical trials of AD-related treatments and other types of AD research.

PMID:
23642575
DOI:
10.1016/j.mcna.2013.01.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center